320337-13-1Relevant academic research and scientific papers
CANCER TREATMENT METHOD
-
, (2016/03/12)
A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE
-
Page/Page column 60, (2011/02/24)
Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.
CANCER TREATMENT METHOD
-
, (2010/02/14)
A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.
Anilinoquinazolines as protein tyrosine kinase inhibitors
-
Page/Page column 74, (2008/06/13)
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
Anilinoquinazaolines as protein tyrosine kianse inhibitors
-
Page/Page column 46, (2008/06/13)
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
Cancer treatment method
-
, (2008/06/13)
A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
